143 related articles for article (PubMed ID: 24800421)
1. Identificationof potential lung cancer biomarkers by liquid chromatography tandem mass spectrometry-based proteomics analysis of secretomes of two lung cancer cell lines.
Shevchenko VE; Kovalev SV; Arnotskaya NE; Kudryavtsev IA
Eur J Mass Spectrom (Chichester); 2013; 19(5):377-89. PubMed ID: 24800421
[TBL] [Abstract][Full Text] [Related]
2. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines.
Planque C; Kulasingam V; Smith CR; Reckamp K; Goodglick L; Diamandis EP
Mol Cell Proteomics; 2009 Dec; 8(12):2746-58. PubMed ID: 19776420
[TBL] [Abstract][Full Text] [Related]
3. Comparative membrane proteomics analyses of breast cancer cell lines to understand the molecular mechanism of breast cancer brain metastasis.
Peng W; Zhang Y; Zhu R; Mechref Y
Electrophoresis; 2017 Sep; 38(17):2124-2134. PubMed ID: 28523741
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Secretomic Analysis Identifies Extracellular Protein Factors That Modulate the Metastatic Phenotype of Non-Small Cell Lung Cancer.
Hu R; Huffman KE; Chu M; Zhang Y; Minna JD; Yu Y
J Proteome Res; 2016 Feb; 15(2):477-86. PubMed ID: 26736068
[TBL] [Abstract][Full Text] [Related]
5. Global and Targeted Proteomics of Prostate Cancer Cell Secretome: Combination of 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry and In Silico Selection Selected Reaction Monitoring Analysis.
Nurdin A; Hoshi Y; Yoneyama T; Miyauchi E; Tachikawa M; Watanabe M; Terasaki T
J Pharm Sci; 2016 Nov; 105(11):3440-3452. PubMed ID: 27665127
[TBL] [Abstract][Full Text] [Related]
6. Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-Free LC-MS/MS Approach.
Beretov J; Wasinger VC; Millar EK; Schwartz P; Graham PH; Li Y
PLoS One; 2015; 10(11):e0141876. PubMed ID: 26544852
[TBL] [Abstract][Full Text] [Related]
7. Discovery of putative pancreatic cancer biomarkers using subcellular proteomics.
McKinney KQ; Lee YY; Choi HS; Groseclose G; Iannitti DA; Martinie JB; Russo MW; Lundgren DH; Han DK; Bonkovsky HL; Hwang SI
J Proteomics; 2011 Jan; 74(1):79-88. PubMed ID: 20807598
[TBL] [Abstract][Full Text] [Related]
8. Relative protein quantification and accessible biology in lung tumor proteomes from four LC-MS/MS discovery platforms.
Stewart PA; Fang B; Slebos RJ; Zhang G; Borne AL; Fellows K; Teer JK; Chen YA; Welsh E; Eschrich SA; Haura EB; Koomen JM
Proteomics; 2017 Mar; 17(6):. PubMed ID: 28195392
[TBL] [Abstract][Full Text] [Related]
9. An off-line high pH reversed-phase fractionation and nano-liquid chromatography-mass spectrometry method for global proteomic profiling of cell lines.
Wang H; Sun S; Zhang Y; Chen S; Liu P; Liu B
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 974():90-5. PubMed ID: 25463202
[TBL] [Abstract][Full Text] [Related]
10. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry.
Ralhan R; Desouza LV; Matta A; Tripathi SC; Ghanny S; Datta Gupta S; Bahadur S; Siu KW
Mol Cell Proteomics; 2008 Jun; 7(6):1162-73. PubMed ID: 18339795
[TBL] [Abstract][Full Text] [Related]
11. Identification and quantification of preterm birth biomarkers in human cervicovaginal fluid by liquid chromatography/tandem mass spectrometry.
Shah SJ; Yu KH; Sangar V; Parry SI; Blair IA
J Proteome Res; 2009 May; 8(5):2407-17. PubMed ID: 19271751
[TBL] [Abstract][Full Text] [Related]
12. The secretome signature of malignant mesothelioma cell lines.
Manfredi M; Martinotti S; Gosetti F; Ranzato E; Marengo E
J Proteomics; 2016 Aug; 145():3-10. PubMed ID: 26921831
[TBL] [Abstract][Full Text] [Related]
13. AGR2 as a potential biomarker of human lung adenocarcinoma.
Chung K; Nishiyama N; Wanibuchi H; Yamano S; Hanada S; Wei M; Suehiro S; Kakehashi A
Osaka City Med J; 2012 Jun; 58(1):13-24. PubMed ID: 23094510
[TBL] [Abstract][Full Text] [Related]
14. Comparative proteomic analysis of non-small-cell lung cancer and normal controls using serum label-free quantitative shotgun technology.
Pan J; Chen HQ; Sun YH; Zhang JH; Luo XY
Lung; 2008; 186(4):255-261. PubMed ID: 18465169
[TBL] [Abstract][Full Text] [Related]
15. Exploration of differentially expressed plasma proteins in patients with lung adenocarcinoma using iTRAQ-coupled 2D LC-MS/MS.
Li W; Zheng H; Qin H; Liu G; Ke L; Li Y; Li N; Zhong X
Clin Respir J; 2018 Jun; 12(6):2036-2045. PubMed ID: 29363881
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers.
Whelan SA; Lu M; He J; Yan W; Saxton RE; Faull KF; Whitelegge JP; Chang HR
J Proteome Res; 2009 Aug; 8(8):4151-60. PubMed ID: 19522481
[TBL] [Abstract][Full Text] [Related]
17. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.
Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF
J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
19. Reaching for the deep proteome: recent nano liquid chromatography coupled with tandem mass spectrometry-based studies on the deep proteome.
Choi YS
Arch Pharm Res; 2012 Nov; 35(11):1861-70. PubMed ID: 23212627
[TBL] [Abstract][Full Text] [Related]
20. The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context.
Schaaij-Visser TB; de Wit M; Lam SW; Jiménez CR
Biochim Biophys Acta; 2013 Nov; 1834(11):2242-58. PubMed ID: 23376433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
